Mayo Clinic Boosts Brain Cancer Treatment Success

Scientists at Mayo Clinic just found a way to turn the immune system against glioblastoma, one of the most aggressive cancers known to medicine.

The research team discovered that blocking a protein called MALT1 can flip a biological switch in immune cells surrounding brain tumors. Instead of protecting the cancer, these reprogrammed cells start attacking it.

Glioblastoma kills most patients within 15 months of diagnosis. Despite surgery, radiation, and chemotherapy, the cancer almost always returns because it creates a protective shield using the body's own immune cells.

Dr. Juliana Yerneni led the study published in Nature Communications. Her team found that combining MALT1 inhibitors with temozolomide, the standard chemotherapy for glioblastoma, worked far better than chemotherapy alone.

In preclinical models, the combination substantially increased median survival compared to traditional treatment. The MALT1 inhibitor also slowed tumor growth when used by itself.

The breakthrough addresses why glioblastoma is so hard to treat. The tumor manipulates surrounding immune cells to dampen the body's natural cancer-fighting response.

"Our findings point to a potential approach to disrupting that protection and, importantly, to making an existing treatment more effective," says Dr. Yerneni, a researcher in Mayo Clinic's Department of Laboratory Medicine and Pathology.

Glioblastoma accounts for roughly 5% of childhood brain cancers and is the most common malignant brain tumor in adults. Current treatments buy time but cannot cure the disease.

Why This Inspires

This discovery matters because it tackles two problems at once. It helps existing treatments work better while turning the immune system into an ally rather than an obstacle.

Dr. Linda McAllister-Lucas, pediatric oncologist and co-senior author, says the goal is understanding how glioblastoma communicates with immune cells to protect itself. These discoveries can identify new treatments that improve outcomes for patients facing this devastating disease.

The research opens pathways that didn't exist before. Instead of just attacking cancer cells directly, doctors may soon help patients' own immune systems join the fight.

More research will determine which glioblastoma subtypes respond best to MALT1-targeted therapy before moving to human trials. For thousands of families facing this diagnosis each year, this represents real hope for better outcomes ahead.